U.S.-listed shares of Evaxion Biotech A/S jumped about 17% in premarket trading on Tuesday after the company said the Food and Drug Administration has allowed a Phase 2b clinical trial testing its experimental cancer vaccine to move forward. The study is evaluating Evaxion's EVX-01 in combination with Merck & Co. Inc.'s Keytruda as a treatment for metastatic melanoma in Australia, Europe, and the U.S. Erik Heegaard, Evaxion's chief medical officer, said the FDA's decision "is an important...
READ FULL ARTICLE »
Become a member to take advantage of more features, like commenting and voting.
Register or sign in today!